RecallClass 4 · Caution in use

Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28

Issued 8 Jun 2026 · EL(26)A/28 · Cadila Pharmaceuticals Limited, Dholka, India

Read and act on the official notice on GOV.UK

Class 4 recall — Caution in use. The MHRA uses Class 4 when: Usually minor defects in packaging or other printed materials.
What all four recall classes mean
ClassActionThe MHRA's definition
Class 1Immediate actionThe defect presents a risk of death or disability.
Class 2Action within 48 hoursThe defect may cause mistreatment or harm to the patient, but it is not life-threatening or serious.
Class 3Action within 5 daysThe defect is unlikely to cause harm to the patient.
Class 4 this recallCaution in useUsually minor defects in packaging or other printed materials.

A Class 1 recall usually comes with a National Patient Safety Alert. Source: MHRA, safety communications.

The MHRA's summary

Cadila Pharmaceuticals Limited has informed the MHRA of an error with the European Article Number (EAN) barcode on the cartons of a batch of Mirtazapine 30mg Film-Coated Tablets distributed in Crescent Pharma Limited livery.

Affected batches

As listed by the MHRA, exactly as published. Always check against the GOV.UK notice before acting.

Batch numberExpiryPack sizeFirst distributed
Mirtazapine 30mg Tablets (Crescent Pharma Limited livery)
ET570E501208/202828b09/04/2026

MHRA's audience tags: Dispensing GP practices, General practice, Pharmacy

Pharmshark is not an official alerting route. Make sure your pharmacy receives alerts directly from the MHRA and through your organisation, and always act on the official GOV.UK notice.

Source: the MHRA on GOV.UK. Contains public sector information licensed under the Open Government Licence v3.0. Pharmshark is not affiliated with or endorsed by the MHRA.